Invivyd (NASDAQ:IVVD) Given “Buy” Rating at HC Wainwright

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Several other brokerages have also recently weighed in on IVVD. Morgan Stanley decreased their price target on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Invivyd in a research note on Monday. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $7.89.

Invivyd Trading Down 19.5 %

Shares of IVVD stock traded down $0.35 on Monday, hitting $1.43. 8,789,516 shares of the stock were exchanged, compared to its average volume of 24,734,166. The firm has a market capitalization of $170.46 million, a P/E ratio of -0.73 and a beta of 0.61. Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $4.74. The business has a 50-day moving average of $0.79 and a 200 day moving average of $0.86.

Insider Activity

In other Invivyd news, Director Terrance Mcguire sold 160,400 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $0.59, for a total transaction of $94,636.00. Following the sale, the director now directly owns 4,202,679 shares of the company’s stock, valued at approximately $2,479,580.61. This represents a 3.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders sold 816,466 shares of company stock valued at $423,214. 17.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of IVVD. Mithril II GP LP acquired a new stake in Invivyd in the 4th quarter valued at about $4,981,000. State Street Corp raised its stake in Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after buying an additional 35,904 shares during the period. Deutsche Bank AG lifted its position in shares of Invivyd by 35.2% in the fourth quarter. Deutsche Bank AG now owns 874,406 shares of the company’s stock valued at $385,000 after buying an additional 227,463 shares during the last quarter. Two Sigma Investments LP boosted its stake in shares of Invivyd by 125.3% during the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock worth $163,000 after acquiring an additional 204,188 shares during the period. Finally, Two Sigma Advisers LP increased its holdings in shares of Invivyd by 1,276.5% during the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock worth $135,000 after acquiring an additional 282,100 shares during the last quarter. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.